Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant H7 hemagglutinin influenza vaccine + Advax-1 adjuvant
- Development stage
- Unknown
- Lead developer
- Vaxine
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Recombinant H7 hemagglutinin influenza vaccine + Advax-1 adjuvant is an investigational monovalent subunit vaccine candidate developed by Vaxine Pty Ltd for the prevention of H7N9 avian influenza. The vaccine utilizes a recombinant H7 hemagglutinin (HA) protein, typically expressed in a baculovirus system, as the primary antigen to elicit neutralizing antibodies. It is formulated with Advax-1, a proprietary adjuvant composed of delta-inulin (a crystalline isoform of inulin). Advax-1 acts as a potent immune enhancer that stimulates both Th1 and Th2 pathways and memory T-cell responses without inducing the excessive local inflammation or reactogenicity often seen with traditional adjuvants. The combination has been evaluated in Phase 1 and Phase 2 clinical trials to address the pandemic threat posed by H7N9 viruses.
- Other names
- recombinant H7N9 vaccine + Advax-1H7N9-Advax vaccineH-7N9-Advax vaccineH 7N9-Advax vaccinerecombinant H7 hemagglutinin influenza vaccine with Advax-1 adjuvant
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on recombinant H7 hemagglutinin influenza vaccine + Advax-1 adjuvant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant H7 hemagglutinin influenza vaccine + Advax-1 adjuvant.